Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry-Reference-Cited by-同舟云学术

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry

Published:2021-02-15 Issue:2 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Lockshin Benjamin¹,Cronin Angel²,Harrison Ryan W.²,McLean Robert R.²,Anatale‐Tardiff Laura²,Burge Russel³,Zhu Baojin³,Malatestinic William N.³,Atiya Bilal³,Murage Mwangi J.³,Gallo Gaia³,Strober Bruce⁴⁵,Van Voorhees Abby⁶

Affiliation:

1. US Dermatology Partners Rockville Maryland USA

2. Corrona LLC Waltham Massachusetts USA

3. Eli Lilly and Company Indianapolis Indiana USA

4. Yale University New Haven Connecticut USA

5. Central Connecticut Dermatology Research Cromwell Connecticut USA

6. Eastern Virginia Medical School Norfolk Virginia USA

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14808

Reference41 articles.

1. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA

2. A cross-sectional study in young adults with psoriasis: potential determining factors in quality of life, life course and work productivity

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab

4. Psoriasis

5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis;Sbidian E;Cochrane Database Syst Rev,2017

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia;Journal of Dermatological Treatment;2024-08-05

2. Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study;JEADV Clinical Practice;2024-07-04

3. Exposure–response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis;Journal of the European Academy of Dermatology and Venereology;2024-05-08

4. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis;Drugs;2024-04-17

5. Advantages of IL-17 inhibitor, ixekizumab, in the treatment of severe psoriasis;Meditsinskiy sovet = Medical Council;2024-03-08